On the afternoon of June 18th, on the eve of the opening of the 21st World Pharmaceutical Raw Materials China Exhibition (CPHI & PMEC China), the 12th China and World Pharmaceutical Entrepreneurs Summit was successfully held.
The summit was co-sponsored by China Chamber of Commerce for Import and Export of Pharmaceutical and Health Products and Informa Markets, co-organized by Shanghai Bohua International Exhibition Co., LTD., and strongly supported by Suzhou Wuzhong District People's Government.
After a gap of two years, the theme of this summit is "looking for 'certainty' in uncertainty," and invited government leaders such as business and drug authorities and industry personnel to gather together to discuss the situation and problems faced in the post-epidemic era, and find ways to develop high-quality industry internationalization.
Founding President of China Drug Regulatory Society Shao Mingli, President Zhang Wei, Deputy Director of Foreign Trade Department of Ministry of Commerce Li Shuo, Member of Party Group and Deputy Director of Shanghai Drug Regulatory Administration Guo Shuting, Deputy Commissioner of Shanghai Commissioner Office of Ministry of Commerce He Shaojun, Director of China Service Outsourcing Research Center of Ministry of Commerce CAI Yudong, Secretary of Suzhou Wuzhong District Party Committee Ding Lixin, Li Ye, Vice Governor of Wuzhong District People's Government of Suzhou City, Zhou Hui, President of China Medical Insurance Chamber of Commerce, Meng Dongping, Party Secretary, Tan Shengcai, Vice president, Zhang Xueqiang, general manager of Shanghai Bohua International Exhibition Co., LTD., and other leaders and guests attended the meeting. The conference was presided over by Wang Maochun, vice president of the Medical Insurance Chamber of Commerce. Nearly 300 representatives of pharmaceutical companies and institutions attended the summit.
Conference site
Opening address
Shao Mingli delivered a speech
Shao Mingli, founding president of the China Drug Regulatory Society, delivered the opening speech, saying that in the past three years, the occurrence of the novel coronavirus epidemic has had a significant impact on the global pharmaceutical industry chain and supply chain, and the international development of China's pharmaceutical industry is facing new situations and challenges. In the post-epidemic era, how to better "go out" and "bring in" Chinese pharmaceutical companies, and more widely participate in international cooperation and market competition, is the current problem that Chinese pharmaceutical people need to calmly face, deeply think about, and can discuss with international counterparts. In recent years, the policy environment and internal and external conditions for the development of China's pharmaceutical industry have undergone profound changes, and it has entered a high-quality development stage of accelerating innovation-driven, promoting the modernization of the industrial chain, and integrating into the global industrial system at a higher level. In order to achieve the goal of drug safety and quality assurance approaching the international advanced level as soon as possible, the key is to build a solid scientific foundation for drug regulation, vigorously practice the concept of scientific regulation, make full use of modern scientific and technological means, and build a regulatory science system that conforms to China's national conditions and conforms to the development trend of international regulation.
Guo Shuting delivered a speech
Guo Shuting, member of the Party group and deputy director of the Shanghai Drug Administration, said in his speech that internationalization is the only way for the future development of China's pharmaceutical industry. In recent years, China's drug supervision has been continuously in line with international standards, and at the industry level, on the basis of the steady development of traditional API exports, more innovative products have been carried out overseas clinical, registration and commercialization layout. Biopharmaceutical is one of the three leading industries in Shanghai with key development breakthroughs. Benefiting from the measures taken by the State Food and Drug Administration to continuously deepen the reform of the review and approval system and encourage the innovation of drugs and medical devices, the scale of the biopharmaceutical industry in Shanghai has grown steadily, the industrial structure has been optimized and upgraded, and pharmaceutical innovation activities have continued to burst out.
He introduced that four class 1 new drugs were approved in Shanghai in 2022, ranking first in the country; So far this year, 3 Class 1 new drugs have been approved, ranking among the best in the country. In 2022, a total of 16 items were entered into the national innovative medical device special review procedure, and 9 registration certificates were approved through the special review channel; So far this year, it has entered 4 innovation channels, a total of 81, 3 innovation registration certificates were approved, and a total of 36 registration certificates, ranking second in the country.
Speech by Zhou Hui
Zhou Hui, president of the China Medical Insurance Chamber of Commerce, said the COVID-19 epidemic has had a major impact on all walks of life, and so has China's pharmaceutical trade. Since the outbreak of the epidemic, the fluctuations in the export of epidemic prevention products at different stages have profoundly affected the overall trend of China's pharmaceutical foreign trade in the past three years. Despite experiencing many challenges such as unstable demand, poor logistics, soaring raw material prices, and exchange rate fluctuations, with the help of relevant policies, and with the advantages of its own industrial chain and supply chain, China's pharmaceutical foreign trade has still achieved excellent results, showing full resilience in development. At present, the risk of world economic recession is rising, the growth of external demand is slowing down significantly, the international supply chain pattern is accelerating restructuring, and the environment for foreign trade development is extremely severe. Pharmaceutical foreign trade is also affected by the complex external environment, while ushering in more intense market competition under global localized production. It is extremely important for pharmaceutical enterprises to actively respond to the trend and find an effective path for the high-quality development of China's pharmaceutical industry. For more than 20 years, CPHI China has been committed to providing a high-end, open and sharing exchange platform for domestic and foreign pharmaceutical industry, and actively promoting China's pharmaceutical industry to connect with the global market.
Ding Lixin delivered a speech
Ding Lixin, Secretary of Wuzhong District Party Committee of Suzhou City, said that Wuzhong and Shanghai are connected by "water", because of "production", with unique location advantages and resource endowment, open arms, welcome talents from all over the world, and rush to each other in this hot land of innovation and entrepreneurship, livable and suitable business. Wuzhong is full of vigor and bright future. Wuzhong District adheres to the development strategy of "industrial strong area and innovation leading", and the three major industrial innovation clusters of robotics and intelligent manufacturing, biomedical and health, and new generation information technology have risen rapidly. Wuzhong has listed biomedicine and health industry as the three leading industries in the region, and has made every effort to build a new landmark of Wuzhong pharmaceutical industry with regional competitiveness. Walking into Wuzhong is walking into the prosperous career prospects, the high momentum of hundreds of backyards, and the unlimited broad platform, together with the brave people, in the "most beautiful place in Taihu Lake", choose to forge ahead.
Zhang Xueqiang delivered a speech
Zhang Xueqiang, general manager of Shanghai Bohua International Exhibition Co., LTD., said that since 2023, the favorable environment of international exchange policy tends to pick up and the continuous release of incremental market demand has boosted confidence in promoting the continuous improvement of economic operation and injected a boost to the healthy development of pharmaceutical foreign trade. Having been engaged in the pharmaceutical industry for more than 20 years, CPHI China will be grandly opened on June 19 at Shanghai New International Expo Center after a two-year absence. As a large trade platform rooted in China in the global series of exhibitions, the exhibition will gather more than 3,300 exhibitors and 55,000 + professional visitors this year, and the scale will exceed 200,000 square meters. After years of accumulation and precipitation, CPHI & PMEC China has continuously innovated and upgraded, and has become the preferred comprehensive business platform for the pharmaceutical industry integrating brand display, industrial chain integration and international trade.
Keynote speech
Li Shuo's speech
Pharmaceutical foreign trade enterprises also made positive contributions, which strongly supported the stability and quality of import and export. He pointed out that the foreign trade situation in 2023 is complex and severe, but at the same time, we must see the advantages, resilience and potential of China's foreign trade. He said that the Party Central Committee and The State Council attach great importance to the development of pharmaceutical trade. The stable foreign trade policy introduced this year aims to effectively help enterprises rescue and solve difficulties, mainly covering five areas: first, to better help enterprises explore the market, second, to further play the role of exhibitions, third, to further strengthen foreign trade security services measures, fourth, to promote the better implementation of new foreign trade formats and new models of policy, and fifth, to further strengthen international cooperation. He said that in the next stage of work, we will continue to improve the level of trade facilitation of pharmaceutical products, help the majority of pharmaceutical enterprises to explore the international market, and jointly promote the high-quality development of trade in pharmaceutical products.
Li Dongming gave a speech
Li Dongming, vice president of Shanghai Pharma, gave a speech with the theme of "Thinking on the International Development of pharmaceutical Enterprises under the New Situation". He made an in-depth analysis on "Why International development" and "International layout and strategy", and introduced the practice of international development of Shanghai Pharma.
Li Ye's speech
Li Ye, Deputy Governor of Wuzhong District People's Government of Suzhou City, introduced the investment environment of Wuzhong District of Suzhou City and welcomed the participating enterprises to invest and cooperate in Wuzhong City.
Cui Tianxiong delivered a speech
Cui Tianxiong, Director of Commercial Operations of IQVIA Greater China, delivered a keynote speech on "Global Pharmaceutical Market Development and Outlook", explaining the global pharmaceutical trends in 2022, and analyzing the oncology field, biosimilar market, and small molecule market.
Jiang Yi's speech
Jiang Yi, Vice President of Corning's Innovation Division and Chairman and general manager of Corning Continuous Pharmaceutical Technology Suzhou, delivered the "Opportunities and Prospects of Continuous Pharmaceutical Manufacturing Keynote Speech", introducing the necessity, joint links, opportunities and prospects of continuous manufacturing.
Tong Youjun speech
Tong Youjun, chairman of Dalian Hanwen Information Co., LTD., analyzed how to help pharmaceutical enterprises explore the international market through trade big data, and focused on the "international market business public service platform" built in conjunction with China Medical Insurance Chamber of Commerce and other national import and export chambers.
Round table discussion
"Belt and Road" 10th anniversary, medical and health cooperation "start again" ˙ Round Table Discussion I
The year 2023 coincides with the 10th anniversary of the "Belt and Road" Initiative, and the cooperation between China and countries and regions along the "Belt and Road" in the field of medicine and health has developed steadily over the past decade. Under the auspices of Yan Libo, Chairman of Jiangsu Kaiyuan Pharmaceutical Co., LTD., Ban Yan, Vice President of Zhongninghua Group and Chairman of Zhejiang Longhua Pharmaceutical Co., LTD., Wu Hao, deputy general manager of China Medical and Health Products Co., LTD., Zhang Qiuying, deputy general manager of Huapao International Pharmaceutical Co., LTD., An Xiaoxia, general manager of Shanghai Dicenol Pharmaceutical Group Co., LTD., Fang Hongjun, director and vice president of Zhejiang Tianyu Pharmaceutical Co., LTD., shared relevant experience on the market development along the "Belt and Road" and had an in-depth discussion on how to develop pharmaceutical foreign trade in the post-epidemic era.
Intelligent manufacturing enables the international development of pharmaceutical industry ˙ Round table Discussion II
Zheng Jinwang, Vice President of Dongfulong Technology Group Co., Ltd. hosted the roundtable discussion on "Intelligent Manufacturing Enables the International Development of the Pharmaceutical Industry", Jiang Yi, Vice President of Innovation Division of Corning Company, Chairman and General manager of Corning Continuous Pharmaceutical Technology Suzhou Company, Zheng Leiming, Managing Director of Colber Pharmaceutical Technology (Shanghai) Co., LTD., Liu Future, Director of Data innovation of Boteng Pharmaceutical Technology Co., LTD., and Wang Hai, IT Head of Tianjing Biological, respectively shared the practice of digitalization and intelligent manufacturing, and discussed the topic of how pharmaceutical companies improve production quality and efficiency through digital intelligence, and the gap between Chinese and foreign pharmaceutical companies in digitalization.
peroration
China and the World Pharmaceutical Entrepreneurs Summit is the main forum of CPHI China Exhibition, which has built a professional, high-end, open and shared exchange platform for the international development of the industry, and is also an annual gathering of new and old friends in the field of pharmaceutical foreign trade and internationalization. We hope to provide more cooperation opportunities for participating enterprises through this platform, and provide more experience and ideas for the high-quality development of industrial internationalization.